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Abstract
Background: Studies have shown that early detection and treatment of neovascular age-related macular
degeneration (NV-AMD) can delay vision loss and blindness. The objective of this study was to evaluate the
efficacy/safety of intravitreal pegaptanib sodium monotherapy in treatment-naïve subjects with newly diagnosed
NV-AMD and to gain insight into characteristics of lesions treated in community-based practices.
Methods: From seven private US practices, charts were retrospectively reviewed on 73 subjects with previously
untreated subfoveal choroidal NV-AMD treated with their first dose of pegaptanib monotherapy on/after 4/1/2005
through 6/5/2006, receiving ≥4 treatments at 6-week intervals over 21 weeks. Primary endpoint: mean visual acuity
(VA) change from baseline to month 6.
Results: 75% of lesions were occult, and 82% were subfoveal. From baseline to month 6, mean VA change was
-0.68 lines; 58% and 16% gained ≥0 and ≥3 lines of VA, and 70% were responders (<3 lines lost). In 35 subjects
with early disease, 80% were responders with a mean gain of 0.46 lines.
Conclusion: Pegaptanib is effective in real-world patients with treatment-naïve NV-AMD in uncontrolled
community-based retina practices.
Background
Age-related macular degeneration (AMD) is a chronic,
progressive disease that results in a loss of central vision
and significant functional impairment. It is the leading
cause of blindness in Western developed countries [1,2].
Neovascular AMD (NV-AMD) represents 10 to 15% of
all AMD cases but accounts for 90% of AMD-related
severe vision loss [3]. Choroidal neovascularization
(CNV) causes disruption of the structure and function
of the retinal pigment epithelium and the retinal photo-
receptors. Prevalence of late forms of AMD (defined as
the presence of NV-AMD or geographic atrophy [4])
increases exponentially with age [5].
Rapid vision loss is a key characteristic of NV-AMD,
such that the proportion of untreated patients who
develop severe vision loss (> 6 lines) can reach up to
42% in 3 years of follow-up [6]. Additionally, patients
with CNV in one eye have an estimated 43% probability
of progression to NV-AMD in the fellow eye within 5
years [7]. Patients with visual impairment from AMD
lose independence, suffer from fall-related injuries,
experience high levels of depression and anxiety,
develop annoying visual hallucinations, and require low
vision aids [8-12]. Direct medical and non-medical costs
and the cost of progression to blindness all contribute
to the economic burden of AMD both to the patient
and to society. Estimated annual societal costs of all
NV-AMD patients in Canada, France, Germany, Spain,
and the United Kingdom are substantial, ranging from
€671 to €3278 million [13].
Studies show that the early detection and treatment of
AMD can delay vision loss and blindness and thus sig-
nificantly reduce the economic burden of the disease
[14,15]. The primary purpose of early treatment ideally * Correspondence: barbara.wirostko@pfizer.com
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improvement. Prior to the development of anti-vascular
endothelial growth factor (VEGF) inhibitors, NV-AMD
patients were treated with laser photocoagulation and
photodynamic therapy (PDT) with verteporfin (Visu-
dyne®). PDT had limited use as it was only approved to
treat the predominantly classic type lesion, representing
approximately 20% of NV-AMD patients [16] and it
merely slowed vision loss [17].
The quest for alternative treatment options in NV-
AMD has been precipitated by the increasing prevalence
of the disease and by the associated side effects and
unsatisfactory outcomes with approved therapies. Anti-
VEGF treatments, such as pegaptanib sodium (Macu-
gen®), ranibizumab (Lucentis®) and bevacizumab (Avas-
tin®), are the first pharmacological treatments to address
an underlying pathological factor of the CNV of NV-
AMD and to address disease progression without
healthy ocular tissue destruction. Pegaptanib sodium, a
selective anti-VEGF therapy approved for the treatment
of all subtypes of NV-AMD, was introduced into the US
market in January 2005. Results from phase II/III pivotal
clinical trials [18,19] showed that pegaptanib was effec-
tive in patients with subfoveal NV-AMD regardless of
lesion subtype (i.e. predominantly classic, minimally
classic, or occult). Approximately 70% of patients treated
with 0.3 mg pegaptanib had stabilised or improved
vision (lost < 15 letters [< 3 lines] compared to baseline)
at 54 weeks compared to 55% of patients receiving stan-
dard-of-care treatment. Additionally, pegaptanib was
well tolerated, with the majority of adverse events being
ocular in nature and transient.
Currently available efficacy and safety data for pegap-
tanib are from clinical trials, which may not accurately
reflect pegaptanib’s real-world use and potential visual
outcomes. Further, there is a need to understand which
disease characteristics define earlier lesions in order to
identify patients who may have a better response to
anti-VEFG therapy (i.e. pegaptanib). We performed a
retrospective chart review study in newly diagnosed NV-
AMD patients initially treated with 0.3 mg pegaptanib
in the US to evaluate actual clinical experience with
intravitreal pegaptanib monotherapy and to explore the
characteristics of lesions in patients in whom a better
response to pegaptanib monotherapy was observed.
Methods
Study design
This retrospective medical chart review study included
73 newly diagnosed NV-AMD subjects recruited from
seven retina specialist offices/clinics in different geo-
graphic regions of the US who were treated with pegap-
t a n i bm o n o t h e r a p y .S u b j e c t sw e r er e q u i r e dt oh a v ea t
least one eye (study eye) that was newly diagnosed with
NV-AMD and that was previously untreated for this
condition prior to pegaptanib therapy. Subjects had
best-corrected Snellen visual acuity (VA) of 20/40 to 20/
200 in the study eye when pegaptanib therapy was
initiated and were free from any other ocular pathology
that would impair VA. Subjects must have received
pegaptanib monotherapy for a minimum of four treat-
ments at 6-week intervals over a 21-week period in the
study eye, with initial therapy on or after 1 April 2005
through 5 June 2006. All subjects were ≥ 50 years of age
and were excluded if they had participated in an investi-
gational drug study within the study period. Site study
staff identified potential charts for review according to
study inclusion and exclusion criteria and contacted
subjects of the potential charts to obtain written
informed consent prior to data abstraction. No medical
interventions or invasive procedures were required by
the study protocol.
This study was conducted according to the tenets of
the Declaration of Helsinki. The study protocol and sub-
ject informed consent document were approved by the
Allendale Investigational Review Board, a central human
investigation review board. This research was compliant
with Health Insurance Portability and Accountability
Act policies and procedures.
Data abstracted
Abstracted chart data included subjects’ demographic
characteristics, NV-AMD diagnosis date, VA at the time
of NV-AMD diagnosis, comorbid medical conditions,
baseline clinical characteristics of the study eye (includ-
ing VA, angiographic subtype, lesion size, lesion charac-
teristics and lesion location based on fluorescein
angiography) prior to pegaptanib monotherapy initia-
tion, date of injection visits, VA assessment at each
injection visit and ocular adverse events.
Endpoints and statistical analysis
The primary endpoint was mean change in best-cor-
rected VA from baseline to month 6. Secondary end-
points included proportions of subjects who gained ≥ 0,
1, 2 and 3 lines of VA and proportion of those who lost
< 3 lines, 3 to < 6 lines and 6 or more lines in best-cor-
rected VA from baseline to month 6. Safety analysis was
performed based on a pre-specified list of adverse events
common with intravitreal injections.
We calculated summary statistics (means and standard
deviations [SD] for continuous variables and frequency
distributions for categorical variables) to describe sample
demographic and clinical characteristics at baseline and
clinical characteristics of study eyes at each treatment
visit. Mean change in VA from baseline was calculated
both in logarithm of the minimum angle of resolution
(logMAR) and in line units of VA at each treatment
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visit.
We compared mean change in VA (logMAR; t-test or
Wilcoxon nonparametric test) and proportions of sub-
jects who gained or lost VA (Fisher’se x a c tt e s t )f r o m
baseline to month 6 between those classified as having
early lesions and those not having early lesions. Two
definitions of early disease (early lesion) from the
V I S I O Ns t u d y[ 2 0 ]w e r eu s e df o rt h ea s s e s s m e n t .D e f i -
nition No.1 defined early disease as a lesion size of < 2
disc areas, baseline VA in the study eye of ≥ 20/80 (≥
54 Early Treatment of Diabetic Retinopathy Study
[ETDRS] letters), and absence of scarring or atrophy
within the lesion. Definition No.2 defined early disease
as occult with no classic CNV, absence of lipid, and bet-
ter VA at baseline in the fellow eye (i.e. worse VA at
baseline in the study eye). Further, we evaluated subject
baseline characteristics and VA change from baseline to
month 6 across study sites to assess whether any differ-
ences in treatment patterns, subject characteristics or
outcomes were observed among sites using t-test, Wil-
coxon test, or Fisher’s exact test, as appropriate.
Statistical significance was evaluated at the 0.05 level
with no adjustments for multiple comparisons. All ana-
lyses were performed using PC-SAS version 9.1 (SAS
Institute, Cary, NC, USA).
Results
Baseline demographics and clinical characteristics
Data were collected between August and November
2006 from 73 NV-AMD subjects’ medical charts. Sub-
ject demographic characteristics and comorbid condi-
tions are summarised in Table 1. The median age of the
subjects was 79 years (range, 58-92 years). A majority of
the subjects were female (62%) and had at least one cor-
morbid disease (86%).
At baseline, the mean (SD) VA in the study eye was
0.62 (0.24) logMAR, equivalent to approximately 20/80
Snellen, and the mean time from NV-AMD diagnosis to
baseline (first treatment) was 2.4 months (Table 2). A
majority of subjects had occult lesions (75%); lesion size
< 4 disc areas (66%); subfoveal lesion locations (82%).
Few subjects had pigment epithelial detachment, retinal
angiomatous proliferation, cystoid macular oedema
(CME), fibrosis or geographic atrophy. Approximately
one-third (34%) had presence of blood reported.
VA change from baseline
Overall sample
On average, subjects’ VA remained stable through the
fourth pegaptanib treatment. There was a slight decline
from baseline to the month 6 visit (mean change: 0.07
logMAR [-0.68 lines]; Table 3), with 58% of subjects
gaining ≥ 0 lines, 16% gaining ≥ 3 lines, 12% losing > 0
to < 3 lines, and 11% losing ≥ 6 lines. In all, 70% of sub-
jects lost <3 lines of VA.
Evaluation of mean VA change from baseline to
month 6 by baseline NV-AMD characteristics showed
that only angiographic subtype was significantly asso-
ciated with VA change: subjects with occult lesions had
improvement in mean VA (-0.01 logMAR [0.09 lines])
while those with predominantly classic and minimally
classic lesions had a decline in mean VA (0.27 and 0.34
logMAR, [-2.64 and -3.50 lines], respectively; overall p-
value = 0.0065 from one-way analysis of variance).
By early disease definitions
Eighteen subjects met early disease definition No.1
(lesion size < 2 disk areas, baseline VA of the study eye
≥ 20/80 and absence of scarring or atrophy), and 35
subjects met early disease definition No. 2 (occult with
Table 1 Baseline demographic characteristics and
comorbid conditions.
Characteristic Study sample
Age (years)
N7 3
Mean (SD) 78.3 (7.0)
Median (range) 79 (58 – 92)
Gender, n (%)
Female 45 (61.6)
Male 27 (37.0)
Missing 1 (1.4)
Ethnicity, n (%)
White, non-Hispanic 26 (35.6)
Missing 47 (64.4)
Reported comorbid disease, n (%) 63 (86.3)
Comorbid disease, n (%)
Diabetes 5 (6.8)
Cancer 13 (17.8)
Asthma 4 (5.5)
Chronic obstructive pulmonary disease 2 (2.7)
Arthritis and rheumatism 22 (30.1)
Headache (migraine, cluster) 1 (1.4)
Chronic neck or back pain 1 (1.4)
Heart disease 12 (16.4)
Stroke 2 (2.7)
Sleep disturbance 1 (1.4)
Comorbid disease categories, n (%)
Ocular* 31 (42.5)
Other 55 (75.3)
Comorbid diseases
†
N6 3
Mean (SD) 3.1 (1.5)
Median (range) 3 (1 – 7)
* Includes diabetic retinopathy, glaucoma, congenital degeneration of the
retina, ocular tumour, cataract, and low vision due to other reasons.
†Among subjects with comorbid conditions.
SD = standard deviation.
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fellow eye at baseline). Subjects with missing data who
could not be classified with regard to early disease defi-
nitions were excluded from the analyses reported below.
Subjects meeting early disease definition No.1 showed
a decline in mean VA at all treatment visits, and a sig-
nificant difference in VA change was observed at the
third visit relative to those who did not meet the defini-
tion (0.08 versus -0.06 logMAR [-0.89 versus 0.61 lines];
p = 0.0283; Table 4). Subjects meeting early disease defi-
nition No.2 showed improvement in mean VA from
baseline at all treatment visits (p < 0.05 for the third,
fourth, and month 6 visits difference between those who
met the definition and those who did not meet the defi-
nition). Additionally, 26% of subjects meeting early dis-
ease definition No.2 had ≥ 3-line gains from baseline to
month 6 compared with only 6% among subjects meet-
ing early disease definition No.1 (Figure 1). Using early
disease definition No.2, 80% of patients were responders
(lost < 3 lines of VA). Mean change in VA from baseline
to month 6 was a loss of 0.16 logMAR (-1.61 lines) for
definition No.1 and an improvement of -0.05 logMAR
(0.46 lines) for definition No.2, with the latter group
showing more favourable outcomes compared to the
entire sample (0.07 logMAR [-0.68 lines]).
Evaluation of baseline subject clinical characteristics
showed that subjects meeting early disease definition
Table 2 Baseline clinical characteristics of study eyes.
Characteristic Study eye
Best-corrected VA (logMAR)
N7 3
Mean (SD) 0.62 (0.24)
Median (range) 0.54 (-0.18 – 1.00)
Time from NV-AMD diagnosis to baseline, months
N7 3
Mean (SD) 2.4 (5.9)
Median (range) 0 (0 – 31)
Angiographic subtype, n (%)
Minimally classic 4 (5.5)
Occult 55 (75.3)
Predominantly classic 11 (15.1)
Missing 3 (4.1)
Lesion size (disc area), n (%)
< 2 26 (35.6)
≥ 2 and < 4 22 (30.1)
≥ 4 11 (15.1)
Missing 14 (19.2)
Lesion location, n (%)
Subfoveal 60 (82.2)
Extrafoveal 1 (1.4)
Juxtafoveal 6 (8.2)
Missing 6 (8.2)
Pigment epithelial detachment, n (%)
Absent 46 (63.0)
Present 16 (21.9)
Missing 11 (15.1)
Retinal angiomatous proliferation, n (%)
Absent 58 (79.5)
Present 1 (1.4)
Missing 14 (19.2)
Cystoid macular oedema, n (%)
Absent 52 (71.2)
Present 7 (9.6)
Missing 14 (19.2)
Fibrosis, n (%)
Absent 57 (78.1)
Present 3 (4.1)
Missing 13 (17.8)
Geographic atrophy, n (%)
Absent 54 (74.0)
Present 10 (13.7)
Missing 9 (12.3)
Presence of blood, n (%)
Yes 25 (34.2)
No 43 (58.9)
Missing 5 (6.8)
Table 2: Baseline clinical characteristics of study eyes.
(Continued)
Estimated percentage of lesion with blood, n (%)
≤ 50% 12 (16.4)
> 50% 3 (4.1)
Missing 58 (79.5)
NV-AMD = neovascular age-related macular degeneration; SD = standard
deviation; VA = visual acuity.
Table 3 Visual acuity (VA; logMAR*) in the study eye by
treatment.
Treatment visit Mean VA Mean VA change from baseline
n Mean (SD) n Mean (SD)
Second treatment 73 0.60 (0.32) 73 -0.02 (0.25) (↑)
Third treatment 73 0.59 (0.28) 73 -0.03 (0.23) (↑)
Fourth treatment 73 0.63 (0.35) 73 0.01 (0.29) (↓)
Month 6 visit 73 0.69 (0.39) 73 0.07 (0.33) (↓)
* ↑ improved; ↓ declined. Negative logMAR changes indicate improvement;
positive logMAR changes indicate declination.
LogMAR = logarithm of the minimum angle of resolution; SD = standard
deviation.
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AMD diagnosis to baseline assessment while those who
did not meet the definition for early disease had a mean
of 3.1 (median 0.0) months, a difference that did not
reach statistical significance in either the mean or the
median. Even though more subjects meeting definition
No.1 had CME (17% versus 10%, respectively) and pig-
ment epithelial detachment (28% versus 20%, respec-
tively) and fewer were reported to have the presence of
blood (22% versus 34%, respectively) compared to those
not meeting the definition, none of the differences
reached statistical significance (Table 5). Subjects meet-
ing early disease definition No.2 had a mean of 2.5
(median 0.0) months from NV-AMD diagnosis to base-
line assessment while those who did not meet this defi-
nition had a mean of 0.9 (median 0.0) months (p-values
not significant). Even though fewer subjects meeting
early disease definition No.2 had CME (3% versus 19%,
respectively) or presence of blood (26% versus 48%,
respectively) and more subjects had pigment epithelial
detachment (31% versus 7%, respectively), only the dif-
ference for pigment epithelial detachment reached sta-
tistical significance (Table 5).
By study sites
When mean VA change from baseline to month 6 was
evaluated by study sites, one site (No.7) showed a mean
VA gain of -0.04 logMAR (0.50 lines) compared to a
mean loss of VA ranging from 0.02-0.30 logMAR (-0.17
to -3.00 lines) for all other sites. Figure 2 shows propor-
t i o n so fs u b j e c t sw i t hV Ac h a n g eb ys i t e .D e m o g r a p h i c
and baseline clinical characteristics of the subjects were
compared between site No.7 and all other sites to
explore any subject or practice characteristics that might
lead to substantially more subjects treated at site No.7
maintaining or improving their VA from baseline to
month 6 compared to other sites (83% versus 49%,
respectively; p = 0.0134; Table 6). There was no statisti-
cally significant difference observed in subjects’ baseline
demographic or clinical characteristics between the sites.
H o w e v e r ,t h em e a nt i m ef r o mN V - A M Dd i a g n o s i st o
Table 4 Mean (SD) change in best-corrected visual acuity (VA; logMAR*) from baseline by early disease definition.
Met definition Did not meet definition
Early disease definition n Mean change (SD) n Mean change (SD) p-value
Definition No.1
†
Baseline to second treatment visit 18 0.04 (0.33) 41 -0.06 (0.21) 0.1702
Baseline to third treatment visit 18 0.08 (0.29) 41 -0.06 (0.20) 0.0283
Baseline to fourth treatment visit 18 0.12 (0.35) 41 -0.04 (0.26) 0.0597
Baseline to month 6 visit 18 0.16 (0.39) 41 0.03 (0.31) 0.1799
Definition No.2
‡
Baseline to second treatment visit 35 -0.06 (0.18) 31 0.03 (0.32) 0.1627
Baseline to third treatment visit 35 -0.09 (0.18) 31 0.03 (0.28) 0.0339
Baseline to fourth treatment visit 35 -0.08 (0.22) 31 0.09 (0.34) 0.0155
Baseline to month 6 visit 35 -0.05 (0.28) 31 0.13 (0.34) 0.0235
* Negative logMAR changes indicate improvement; positive logMAR changes indicate declination.
†Early disease definition No.1: lesion size < 2 disk area, baseline VA study eye ≥ 20/80 Snellen, no scar or atrophy.
‡Early disease definition No.2: occult and better VA at baseline in fellow eye (worse in study eye).
LogMAR = logarithm of the minimum angle of resolution; SD = standard deviation.
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Figure 1 Distribution of study eye visual acuity change from
baseline to month 6 by early lesion definition.
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subjects compared to that of the other sites overall (0.33
versus 3.13 months, respectively; p = 0.0808), and sub-
stantially more subjects at site No.7 did not have geo-
graphic atrophy (94% versus 67%, respectively; p =
0.0545).
Ocular safety
Pegaptanib appears to be safe for use (Table 7). There
was one report of endophthalmitis and two reports of
geographic atrophy (occurrence rates of 0.003 and
0.006, respectively, in 326 injections), but the history of
these subjects is not known.
Discussion
The efficacy-related findings of this real-world observa-
tional study are similar to those previously reported in
pegaptanib clinical trials. In the current study, the mean
change in VA from baseline to month 6 was a decline
of -0.68 lines (0.07 logMAR), and 70% of subjects lost
fewer than three lines. The VISION trials [18] showed a
decline of approximately 8 letters, and 70% of subjects
lost fewer than three lines of VA after treatment over a
period of 54 weeks.
There is no universally accepted definition of early
C N Vs e c o n d a r yt oA M D .T h ee a rly lesion definitions
used in this analysis were based on those used in the
exploratory analysis of the VISION study results [20],
matching as closely as possible those definitions using
the data we had available. Subjects in our study who
met early definition No.2 had significantly greater
improvement in VA from baseline to month 6 com-
pared to the decline in VA in those who did not meet
the definition (-0.05 versus 0.13 logMAR [0.46 versus
-1.29 lines], respectively; p = 0.0235). This result was
likely driven by the high proportion of patients with
occult lesions in the study while few subjects with pre-
dominantly classic or minimally classic lesions were
included. This suggests that clinicians when selecting
out earlier lesions are defining these lesions with occult
characteristics. Our current study found that, on aver-
age, subjects with occult lesions treated with pegaptanib
had an improvement in VA from baseline to month 6
while subjects with predominantly classic or minimally
classic lesions had a decline in VA (-0.01 versus 0.27
versus 0.34 logMAR [0.09 versus -2.64 versus -3.50
lines], respectively; p = 0.0065).
In this study, we observed a significant difference in
clinical efficacy in subjects across study sites. In parti-
cular, 83% of subjects treated at site No.7 showed
either an improvement or maintenance of VA from
baseline to month 6, with a mean improvement of
-0.04 logMAR (0.50 lines), while subjects from all
other sites had a mean decline of 0.11 logMAR (-1.07
lines), with only 49% of subjects showing either an
improvement or maintenance of VA (p = 0.0134). The
earlier treatment of subjects at site No.7 might have
accounted for the better results - the mean time from
NV-AMD diagnosis to treatment was 0.3 months for
site No.7 compared to 3.1 months for all other sites (p
= 0.0808). Whether or not anti-VEGF efficacy can be
related to the duration of existing CNV disease has not
been clearly defined. In a recent study by Boyer et al.
[21], efficacy of ranibizumab did not appear to differ
across the different quartiles of duration of NV-AMD,
which is the opposite of what we found in this study
with pegaptanib administration.
Although large randomised, prospective studies have
confirmed benefit with treatment, the question remains
as to which type of CNV lesions responds best to treat-
ment. Different characteristics were identified in pre-
vious studies with no consensus. For example, the TAP
[Treatment of Age-related Macular Degeneration with
Photodynamic Therapy] and VIP [Verteporfin in Photo-
dynamic Therapy] Study Groups [22] concluded that
lesion size was a strong predictor of VA outcome based
upon observed PDT treatment and outcome while the
VISION trials [20] found that anti-VEGF treatment of
early lesions (defined on the basis of the combined char-
acteristics of size, lipid, scarring and time of presenta-
tion) had a positive impact on VA outcome. A different
conclusion was drawn from the MARINA study [21]
subanalysis of subjects with minimally classic and occult
lesions treated with ranibizumab in which neither lesion
size nor duration of NV-AMD was found to have a
direct relationship with VA outcomes. Our study also
attempted to evaluate which of the subjects’ baseline
angiographic characteristics had an impact on VA out-
come and found that those who met the early disease
definition using the criteria of occult with no classic
CNV, absence of lipid, and better VA at baseline in the
fellow eye had better VA outcomes. There is no agreed
upon and accepted early lesion definition at the present
time.
This study intended to evaluate newly diagnosed NV-
AMD patients treated with pegaptanib monotherapy.
Even though we did not provide participating clinicians
with a definition of ‘newly diagnosed,’ we did not find
differences in angiographic characteristics across
patients’ time since diagnosis. However, we did observe
a relationship between time since diagnosis and primary
study outcomes of VA change from baseline to month 6
with shorter time being associated with better outcomes.
The finding is consistent with the oncology literature
that shows that younger tumours that are earlier in
their angiogenic process of new blood vessel develop-
ment appear to be more susceptible to certain types of
anti-VEGF therapy [23,24].
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included only those practices and patients who were
willing to participate. Two sites had a total of four
patients who met study inclusion criteria and who were
willing to participate, with one patient having main-
tained VA and the other three having lost more than
three lines from baseline to month 6. We cannot be cer-
tain that these four individuals are representative of the
universe of NV-AMD patients treated in these two prac-
tices. Conversely, one does not know how representative
patients from site No.7 are to the NV-AMD population
either. The sample size of the study limited our ability
to perform multivariate analyses that might better sup-
port interpreting study findings. In addition, although
the proportion of patients losing VA from baseline to
month 6 appears to correlate with the presence of clas-
sic lesions, this is most likely biased by the fact that our
sample included few subjects with classic lesions.
Further, the study did not collect optical coherence
tomography data for each visit, which might have pro-
vided a more accurate summary of NV-AMD character-
istics, enabling us to evaluate the relationship between
VA change and disease characteristics. Finally, the data
were collected for 6 months only; it is not known if the
Table 5 Baseline clinical characteristics of study eyes by early disease definition.
Early disease definition No.1* Early disease definition No.2
†
Characteristic Met
definition
Did not meet
definition
p-
value
Met
definition
Did not meet
definition
p-
value
Best-corrected VA (logMAR), mean (SD) 0.45 (0.10) 0.68 (0.27) 0.0010 0.62 (0.24) 0.64 (0.27) 0.7536
Time from NV-AMD diagnosis to baseline (months),
mean (SD)
1.11 (3.12) 3.12 (6.94) 0.2456 2.49 (5.43) 0.90 (2.77) 0.1488
Angiographic subtype, n (%) 0.6817 <
0.0001
Minimally classic 1 (5.6) 3 (7.3) 0 (0.0) 4 (12.9)
Occult 13 (72.2) 33 (80.5) 35 (100.0) 16 (51.6)
Predominantly classic 4 (22.2) 5 (12.2) 0 (0.0) 11 (35.5)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Lesion location, n (%) 0.1345 1.0000
Subfoveal 14 (77.8) 38 (92.7) 30 (85.7) 28 (90.3)
Extrafoveal 1 (5.6) 0 (0.0) 0 (0.0) 0 (0.0)
Juxtafoveal 2 (11.1) 3 (7.3) 3 (8.6) 2 (6.5)
Missing 1 (5.6) 0 (0.0) 2 (5.7) 1 (3.2)
Pigment epithelial detachment, n (%) 0.5091 0.0202
Present 5 (27.8) 8 (19.5) 11 (31.4) 2 (6.5)
Absent 13 (72.2) 33 (80.5) 19 (54.3) 26 (83.9)
Missing 0 (0.0) 0 (0.0) 5 (14.3) 3 (9.7)
Cystoid macular oedema, n (%) 0.6639 0.0582
Present 3 (16.7) 4 (9.8) 1 (2.9) 6 (19.4)
Absent 15 (83.3) 37 (90.2) 26 (74.3) 22 (71.0)
Missing 0 (0.0) 0 (0.0) 8 (22.9) 3 (9.7)
Fibrosis, n (%) 1.0000 0.1585
Present 0 (0.0) 2 (4.9) 1 (2.9) 2 (6.5)
Absent 18 (100.0) 39 (95.1) 26 (74.3) 27 (87.1)
Missing 0 (0.0) 0 (0.0) 8 (22.9) 2 (6.5)
Geographic atrophy, n (%) 0.1637 0.2125
Present 0 (0.0) 6 (14.6) 4 (11.4) 5 (16.1)
Absent 18 (100.0) 35 (85.4) 25 (71.4) 25 (80.6)
Missing 0 (0.0) 0 (0.0) 6 (17.1) 1 (3.2)
Presence of blood, n (%) 0.5404 0.0806
Yes 4 (22.2) 14 (34.1) 9 (25.7) 15 (48.4)
No 14 (77.8) 27 (65.9) 24 (68.6) 16 (51.6)
Missing 0 (0.0) 0 (0.0) 2 (5.7) 0 (0.0)
* Early disease definition No.1: lesion size < 2 disk area, baseline VA study eye ≥ 20/80 Snellen, no scar or atrophy within the lesion.
†Early disease definition No.2: occult and better VA at baseline in fellow eye (worse in study eye).
LogMAR = logarithm of the minimum angle of resolution; NV-AMD = neovascular age-related macular degeneration; SD = standard deviation; VA = visual acuity.
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ment period.
Conclusion
The efficacy of pegaptanib in community-based practices
appears to confirm findings from the VISION trials and a
published analysis of patients with earlier disease. There
appears to be a trend for patients with earlier lesions to
respond more favourably to pegaptanib. Due to our small
sample size, there was significant variability of outcomes by
site and by patient. Still, shorter time from NV-AMD diag-
nosis to initiation of pegaptanib treatment appears to be
associated with better treatment outcomes and enhanced
clinical benefits. It is a common theme across the medical
and scientific literature that earlier intervention, prior to
permanent damage, is more likely to achieve a beneficial
outcome. Other large NV-AMD clinical studies [21,22]
have attempted to define and interpret outcome based on
lesion characteristics. In this study, though, other disease
characteristics did not seem useful in identifying ap r i o r i
responders to treatment. Further research is warranted to
fully understand and determine NV-AMD disease charac-
teristics that help predict outcomes. Their results will
enable NV-AMD therapy to be targeted to provide the
greatest benefit to both patients and society.
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Table 6 Comparison of baseline characteristics and clinical efficacy between site No.7 versus other sites.
Characteristic Site No.7 Other sites p-value
Baseline best-corrected VA (logMAR)
Mean (SD) 0.61 (0.26) 0.62 (0.24) 0.8429
Time from NV-AMD diagnosis to baseline (months)
N1 8 5 5
Mean (SD) 0.33 (0.77) 3.13 (6.65) 0.0808
Median (range) 0.0 (0–3) 0.0 (0–31)
Angiographic subtype, n (%) 0.1937
Minimally classic 0 (0.0) 4 (7.3)
Occult 12 (66.7) 43 (78.2)
Predominantly classic 5 (27.8) 6 (10.9)
Missing 1 (5.6) 2 (3.6)
Lesion size (disc area), n (%) 0.1376
<2 9 (50.0) 17 (30.9)
≥ 2 and < 4 7 (38.9) 15 (27.3)
≥ 4 1 (5.6) 10 (18.2)
Missing 1 (5.6) 13 (23.6)
Geographic atrophy, n (%) 0.0545
Present 0 (0.0) 10 (18.2)
Absent 17 (94.4) 37 (67.3)
Missing 1 (5.6) 8 (14.5)
Presence of blood, n (%) 0.4277
Present 4 (22.2) 21 (38.2)
Absent 13 (72.2) 30 (54.5)
Missing 1 (5.6) 4 (7.3)
Met early disease definition No.1* 5 (29.4) 13 (31.0) 1.0000
Met early disease definition No.2
† 5 (29.4) 30 (61.2) 0.0281
VA, baseline to month 6 (logMAR)
Mean (SD)
-0.04 (0.22) 0.11 (0.36) 0.0970
VA change, baseline to month 6
Gained ≥ 0 lines 15 (83.3) 27 (49.1) 0.0134
Gained ≥ 3 lines 3 (16.7) 9 (16.4) 1.0000
Lost < 3 lines 1 (5.6) 8 (14.5) 0.4365
Lost ≥ 6 lines 0 (0.0) 8 (14.5) 0.1871
* Early disease definition No.1: lesion size <2 disk area, baseline VA study eye ≥ 20/80 Snellen, no scar or atrophy.
†Early disease definition No.2: occult and better VA at baseline in fellow eye (worse in study eye).
LogMAR = logarithm of the minimum angle of resolution; NV-AMD = neovascular age-related macular degeneration; SD = standard deviation; VA = visual acuity.
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